Atef Halabi

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · British Journal of Clinical Pharmacology · 2010 · 431 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffé method

Wolfgang Junge, Baerbel Wilke, Atef Halabi et al. · Clinica Chimica Acta · 2004 · 242 citations

Pharmacy, Nephrology, Excretion +9

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct <scp>F</scp>actor <scp>X</scp>a inhibitor

Dagmar Kubitza, Angelika Roth, Michael Becka et al. · British Journal of Clinical Pharmacology · 2013 · 202 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin ^*

Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port et al. · Diabetes Obesity and Metabolism · 2011 · 185 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics and pharmacodynamics of ponesimod, a selective <scp>S1P₁</scp> receptor modulator, in the first‐in‐human study

Patrick Brossard, Hartmut Derendorf, Jian Xu et al. · British Journal of Clinical Pharmacology · 2013 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14